TPEX:6242

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Li Kang Biomedical

Market Cap

NT$1.2b

Last Updated

2021/06/18 08:56 UTC

Data Sources

Company Financials

Executive Summary

Li Kang Biomedical Co., Ltd. manufactures and sells supplements, cosmeceutials, and hygienic tea drinks. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has Li Kang Biomedical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6242 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 6242's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

-6.2%

6242

-0.2%

TW Personal Products

1.3%

TW Market


1 Year Return

43.4%

6242

-8.3%

TW Personal Products

48.5%

TW Market

Return vs Industry: 6242 exceeded the TW Personal Products industry which returned -5.5% over the past year.

Return vs Market: 6242 exceeded the TW Market which returned 48.1% over the past year.


Shareholder returns

6242IndustryMarket
7 Day-6.2%-0.2%1.3%
30 Day8.6%3.7%8.1%
90 Day26.9%-5.0%8.0%
1 Year51.0%43.4%-5.1%-8.3%53.3%48.5%
3 Year-2.3%-12.2%-5.8%-13.4%75.9%55.7%
5 Year44.1%21.0%31.7%14.3%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Li Kang Biomedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Li Kang Biomedical undervalued compared to its fair value and its price relative to the market?

14.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6242 (NT$55) is trading below our estimate of fair value (NT$63.72)

Significantly Below Fair Value: 6242 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 6242 is poor value based on its PE Ratio (16.3x) compared to the TW Personal Products industry average (15.5x).

PE vs Market: 6242 is good value based on its PE Ratio (16.3x) compared to the TW market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6242's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6242 is overvalued based on its PB Ratio (2.4x) compared to the TW Personal Products industry average (2.2x).


Future Growth

How is Li Kang Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.8%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Li Kang Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Li Kang Biomedical performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6242 has high quality earnings.

Growing Profit Margin: 6242's current net profit margins (15.6%) are higher than last year (13.5%).


Past Earnings Growth Analysis

Earnings Trend: 6242's earnings have declined by 2.5% per year over the past 5 years.

Accelerating Growth: 6242's earnings growth over the past year (27.3%) exceeds its 5-year average (-2.5% per year).

Earnings vs Industry: 6242 earnings growth over the past year (27.3%) exceeded the Personal Products industry 4.7%.


Return on Equity

High ROE: 6242's Return on Equity (14.4%) is considered low.


Financial Health

How is Li Kang Biomedical's financial position?


Financial Position Analysis

Short Term Liabilities: 6242's short term assets (NT$268.4M) exceed its short term liabilities (NT$120.5M).

Long Term Liabilities: 6242's short term assets (NT$268.4M) exceed its long term liabilities (NT$41.7M).


Debt to Equity History and Analysis

Debt Level: 6242's debt to equity ratio (7.5%) is considered satisfactory.

Reducing Debt: 6242's debt to equity ratio has reduced from 46.2% to 7.5% over the past 5 years.

Debt Coverage: 6242's debt is well covered by operating cash flow (274.2%).

Interest Coverage: 6242 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Li Kang Biomedical current dividend yield, its reliability and sustainability?

5.14%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 6242's dividend (5.09%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).

High Dividend: 6242's dividend (5.09%) is in the top 25% of dividend payers in the TW market (5.01%)


Stability and Growth of Payments

Stable Dividend: 6242 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 6242's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (82.9%), 6242's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Li Kang Biomedical has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Li Kang Biomedical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Li Kang Biomedical Co., Ltd.
  • Ticker: 6242
  • Exchange: TPEX
  • Founded: 1982
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$1.210b
  • Shares outstanding: 22.20m
  • Website: https://www.likangbio.com

Number of Employees


Location

  • Li Kang Biomedical Co., Ltd.
  • No. 29, Huangong Road
  • Yongkang District
  • Tainan City
  • 710
  • Taiwan

Listings


Biography

Li Kang Biomedical Co., Ltd. manufactures and sells supplements, cosmeceutials, and hygienic tea drinks. It also offers tourism factory management, tourism factory management consulting, and telemarketing ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/18 08:56
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.